Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Denmark
  4. Nasdaq Copenhagen
  5. Novo Nordisk A/S
  6. News
  7. Summary
    NOVO B   DK0060534915

NOVO NORDISK A/S

(NOVO B)
  Report
Delayed Nasdaq Copenhagen  -  10:59 2022-09-29 am EDT
764.70 DKK   +0.08%
11:02aEuropean ADRs Move Lower in Thursday Trading
MT
09:05aNovo Nordisk Enters Exclusive Worldwide License Agreement With Ventus Therapeutics
MT
09/28European ADRs Move Higher in Wednesday Trading
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

NOVO NORDISK : Receives a Sell rating from Jefferies

08/05/2022 | 03:39am EDT

The analyst from Jefferies, Peter Welford, maintains his advice to sell. The target price is being increased from DKK 540 to DKK 585.


© MarketScreener with dpa-AFX Analyser 2022
All news about NOVO NORDISK A/S
11:02aEuropean ADRs Move Lower in Thursday Trading
MT
09:05aNovo Nordisk Enters Exclusive Worldwide License Agreement With Ventus Therapeutics
MT
09/28European ADRs Move Higher in Wednesday Trading
MT
09/26Novo Nordisk A/S – Share repurchase programme
GL
09/26Novo Nordisk A/S – Share repurchase programme
GL
09/22Novo Nordisk Says Phase 3a Trial of Once-Weekly Insulin Icodec Met Primary Endpoint
MT
09/22Novo Nordisk's Trial Finds Weekly Insulin More Effective Than Daily Insulin Jabs
MT
09/21European ADRs Move Lower in Wednesday Trading
MT
09/21NOVO NORDISK : Deutsche Bank remains its Buy rating
MD
09/20Octagon Therapeutics Enters Inflammation-Focused Research Alliance with Novo Nordisk
CI
More news
Analyst Recommendations on NOVO NORDISK A/S
More recommendations
Financials
Sales 2022 171 B 22 522 M 22 522 M
Net income 2022 54 527 M 7 166 M 7 166 M
Net cash 2022 1 098 M 144 M 144 M
P/E ratio 2022 31,5x
Yield 2022 1,52%
Capitalization 1 731 B 227 B 227 B
EV / Sales 2022 10,1x
EV / Sales 2023 8,81x
Nbr of Employees 50 816
Free-Float 69,6%
Chart NOVO NORDISK A/S
Duration : Period :
Novo Nordisk A/S Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVO NORDISK A/S
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Last Close Price 764,70 DKK
Average target price 836,08 DKK
Spread / Average Target 9,33%
EPS Revisions
Managers and Directors
Lars Fruergaard Jørgensen President & Chief Executive Officer
Karsten Munk Knudsen Chief Financial Officer & Executive Vice President
Helge Lund Chairman
Henrik Ehlers Wulff Senior Vice President-Diabetes API
Stephen Gough Global Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
NOVO NORDISK A/S3.96%224 155
JOHNSON & JOHNSON-2.75%437 390
ELI LILLY AND COMPANY12.63%317 719
ROCHE HOLDING AG-14.15%273 173
ABBVIE INC.6.79%255 667
PFIZER, INC.-24.76%249 357